Form 4: Labcorp Director Paul Rothman Acquires RSUs
Insider Transaction Report
Labcorp Holdings Inc. Director Paul Rothman reported the acquisition of 733 Restricted Stock Units, increasing his beneficial ownership to 1,670 units.
Summary
- Paul Rothman, a Director of Labcorp Holdings Inc. (LH), acquired 733 Restricted Stock Units (RSUs).
- Each RSU represents the contingent right to receive one share of Labcorp Holdings Inc. Common Stock.
- The acquired RSUs were granted with a transaction price of $0.
- Following this transaction, Paul Rothman beneficially owns an aggregate of 1,670 Restricted Stock Units.
- The 733 Restricted Stock Units are scheduled to vest fully on February 10, 2027.
Sentiment
Score: 6
Explanation: StockSavvy.ai views this as a neutral to slightly positive event, reflecting routine director compensation that aligns interests with shareholders, without indicating any significant operational or financial changes.
Positives
- The acquisition of Restricted Stock Units by a director aligns their interests with those of shareholders, as the value of the units is tied to the company's stock performance.
Future Outlook
The 733 Restricted Stock Units granted to Director Paul Rothman are scheduled to vest fully on February 10, 2027, indicating a future equity payout contingent on continued service and company performance.
Industry Context
StockSavvy.ai notes that the granting of Restricted Stock Units (RSUs) to directors is a common practice in the healthcare and diagnostics industry, serving as a form of long-term incentive compensation to align leadership interests with shareholder value creation.
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| Power of Attorney Grant | Paul Rothman granted a Power of Attorney to Kathryn W. Kyle, authorizing her to execute and file Forms 3, 4, and 5 on his behalf in accordance with Section 16(a) of the Securities Exchange Act of 1934. | 2025-12-09 | This streamlines the process for insider trading compliance filings for the director, ensuring timely and accurate reporting. |
Stakeholder Impact
- Shareholders: The RSU grant aligns the director's financial interests with long-term shareholder value, as the value of the compensation is tied to the company's stock performance.
Next Steps
- The 733 Restricted Stock Units will vest fully on February 10, 2027, at which point they will convert into shares of Labcorp Holdings Inc. Common Stock.
Key Dates
| Date | Description |
|---|---|
| 2025-12-09 | Date Power of Attorney was executed by Paul Rothman, appointing Kathryn W. Kyle as attorney-in-fact for Section 16 filings. |
| 2026-02-10 | Transaction Date for the acquisition of 733 Restricted Stock Units by Paul Rothman. |
| 2026-02-12 | Date the Form 4 was signed and filed. |
| 2027-02-10 | Date the 733 Restricted Stock Units are scheduled to vest fully. |
Recommendation
holdThis Form 4 filing reports a routine equity grant to a director as part of their compensation package. While it indicates continued alignment of management interests with shareholders, it does not provide new material information regarding the company's operational performance, financial health, or strategic direction that would warrant a change in investment recommendation. Therefore, a 'hold' recommendation is appropriate, maintaining existing positions based on broader company fundamentals.
Keywords
LABCORP HOLDINGS INC., LH, Paul Rothman, Restricted Stock Units, RSU, Insider Transaction, Form 4, Director Compensation, Equity Grant
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.